Levy, Antonin
Morel, Daphné
Texier, Matthieu
Sun, Roger
Durand-Labrunie, Jerome
Rodriguez-Ruiz, Maria E
Racadot, Severine
Supiot, Stéphane
Magné, Nicolas
Cyrille, Stacy
Louvel, Guillaume
Massard, Christophe
Verlingue, Loic
Bouquet, Fanny
Bustillos, Alberto
Bouarroudj, Lisa
Quevrin, Clément
Clémenson, Céline
Mondini, Michele
Meziani, Lydia
Tselikas, Lambros
Bahleda, Rastilav
Hollebecque, Antoine
Deutsch, Eric
Article History
Received: 19 September 2023
Accepted: 22 February 2024
First Online: 23 March 2024
Declarations
:
: The trial was approved by the relevant ethics/institutional review board and was completed in accordance with international standards of good clinical practice. All patients provided written informed consent at the time of enrolment.
: E.D. reports grants and personal fees from Roche-Genentech, grants and personal fees from AstraZeneca, grants and personal fees from Merck Serono, grants and personal fees from Boehringer, grants and personal fees from BMS, and grants and personal fees from MSD.N.M. reports grants and personal fees from Merck Serono, grants and personal fees from Bayer, and grants and personal fees from MSD.A.L. reports grants for academic research from PharMamar, Beigene, Roche, AstraZeneca and Amgen.L.V. reports personal fees from Adaptherapy, is CEO of RESOLVED, has received non-personal fees from Pierre-Fabre and Servier, and a grant from Bristol-Myers Squibb, all outside the submitted work. Research Grants from Astrazeneca, BMS, Boehringer Ingelheim, Celsius, EIT Philips, GSK, INCA, IDERA, Janssen, Lombard, Merck, MedImmune, Pierre Fabre, Roche, Sanofi, Servier. Non-financial support (drug supplied) from Astrazeneca, BMS, Boringher Ingelheim, GSK, Idera, Medimmune, Merck, NH Theraguix, Roche.M.R. reports receiving research funding from Roche and Highlight Therapeutics. She also has received speaker’s bureau honoraria from BMS and ROCHE.RS received support from Fondation Bettencourt-Schueller (CCA Inserm-Bettencourt 2020).C. Quevrin was funded by Ligue Contre le Cancer (Ref IP/SC #17563).